Real-world outcomes of first-and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small …
WW Ng, CC Lin, CY Cheng, JS Jiang, SJ Kao, DY Yeh - Plos one, 2021 - journals.plos.org
The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
recommended as first‐line treatment in non‐small cell lung cancer (NSCLC) patients with …
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
[HTML][HTML] Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor …
Results We analyzed 422 patients with EGFR-mutated advanced lung adenocarcinoma
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
receiving first-line gefitinib (n= 195, 46.2%), erlotinib (n= 123, 29.1%), or afatinib (n= 104 …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
The real-world efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
(TKIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR …
Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR …
E Nadler, M Pavilack, JL Espirito, J Clark… - Advances in …, 2020 - Springer
Introduction Epidermal growth factor receptor (EGFR) mutations are observed in
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
approximately 15% of patients with non-small cell lung cancer (NSCLC) in the USA. Little is …
相关搜索
- egfr tyrosine kinase inhibitors
- lung cancer comparison of the effects
- treatment patterns kinase inhibitors
- lung cancer meta analysis
- large real world cohort
- gefitinib and erlotinib egfr mutation
- gefitinib and erlotinib survival benefits
- safety analysis egfr tki
- egfr tyrosine treatment patterns
- t790m mutation clinical outcomes
- asian patients egfr mutation
- egfr mutations clinical outcomes
- survival benefits egfr mutation